NCT07447206

Vascular Intervention Strategies Trial for Alzheimer's

Vascular Intervention Strategies Trial for Alzheimer's (VISTA)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of Southern California · Academic / Other
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.

Conditions

• Hypertension
• Hypercholesterolemia
• Dementia Risk Factors

Interventions

Type	Name	Description
DRUG	Angiotensin Receptor Blockers (ARBs)	Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes blood pressure management with angiotensin receptor blockers (ARBs).
DRUG	Hydrophilic Statins or Non-Statin Alternative	Participants receive pharmacist-led management of vascular risk factors over a six-month period. This includes cholesterol management with hydrophilic statins or a non-statin alternative if statins are not appropriate.

Timeline

• Start date: 2026-03-01
• Primary completion: 2027-06-01
• Completion: 2028-06-01
• First posted: 2026-03-03
• Last updated: 2026-03-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study